Compare GRFS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | ALKS |
|---|---|---|
| Founded | 1940 | 1987 |
| Country | Spain | Ireland |
| Employees | 23800 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.5B |
| IPO Year | N/A | 2012 |
| Metric | GRFS | ALKS |
|---|---|---|
| Price | $8.71 | $29.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $10.15 | ★ $43.43 |
| AVG Volume (30 Days) | 608.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $5.33 | $24.06 |
| Revenue Next Year | $6.50 | $4.53 |
| P/E Ratio | ★ $18.67 | $20.30 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.19 | $25.17 |
| 52 Week High | $11.14 | $36.32 |
| Indicator | GRFS | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 34.39 |
| Support Level | $8.66 | $29.20 |
| Resistance Level | $9.11 | $31.69 |
| Average True Range (ATR) | 0.27 | 1.13 |
| MACD | -0.08 | -0.53 |
| Stochastic Oscillator | 27.18 | 8.69 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.